Skip to main content
诺思兰德 logo

诺思兰德 — Investor Relations & Filings

Ticker · 920047 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 539 across all filing types
Latest filing 2022-07-05 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920047

About 诺思兰德

https://www.northland-bio.com/

Northland Biotech focuses on the research, development, and commercialization of gene therapies and recombinant protein pharmaceuticals. The company’s primary therapeutic areas include cardiovascular diseases, peripheral arterial diseases, and ophthalmology. Its core R&D pipeline features NL003, a hepatocyte growth factor gene therapy targeting critical limb ischemia, and NL005, a recombinant human thymosin beta 4 for treating myocardial ischemia. Beyond its innovative pipeline, the company maintains advanced manufacturing facilities for biologics and ophthalmic preparations, producing a range of specialized eye drops. By leveraging its proprietary technology platforms, Northland Biotech aims to provide effective treatments for chronic and degenerative conditions through advanced molecular medicine.

Recent filings

Filing Released Lang Actions
第一期股权激励计划预留部分股票期权授予结果公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the results of a stock option grant under an equity incentive plan. It details the number of options granted, the recipients, exercise price, vesting schedule, performance conditions, and the expected accounting impact. It is a formal announcement of the stock option grant results rather than a financial report or detailed management discussion. The document length is 2377 characters, which is relatively short and focused on a specific corporate action. This fits the category of a Regulatory Filing (RNS) as it is a formal disclosure of a corporate event that does not fall under other specific categories like Annual Report, Earnings Release, or Capital Update. Therefore, the appropriate classification is Regulatory Filings (RNS).
2022-07-05 Chinese
关于取得发明专利授权的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of an invention patent authorization from the National Intellectual Property Office. It details the patent name, patent number, and the impact on the company. There is no indication of financial data, regulatory filings, or report publications. The content is a formal announcement about intellectual property rights, which does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is a regulatory announcement about a patent grant, which is best classified under Regulatory Filings (RNS) as it does not fit any other specific category.
2022-07-05 Chinese
股权激励计划部分股票期权注销完成公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the cancellation of part of the company's stock options under its equity incentive plan. It details the number of options cancelled, the reasons for cancellation, and the impact on the company's financial status. There is no indication of a full financial report, audit, or earnings release. The content focuses on changes related to stock options, which is a capital structure change. The document is relatively short (1048 characters) and is a formal announcement of a corporate action related to share capital. Therefore, it fits best under the category of Share Issue/Capital Change (SHA).
2022-07-03 Chinese
2022年第一次临时股东大会通知公告（提供网络投票）
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice announcing the convening of the 2022 first extraordinary general meeting of shareholders (临时股东大会) for Beijing Northland Biotech Co., Ltd. It details the meeting date, voting methods (including online voting), agenda items, registration procedures, and contact information. It does not contain financial statements, audit results, or detailed financial data. It is not a report itself but an announcement about a shareholders meeting. Therefore, it fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2022-06-28 Chinese
独立董事关于第五届董事会第二十次会议的独立意见
Capital/Financing Update Classification · 95% confidence The document is an independent directors' opinion regarding the termination of a specific share issuance to certain investors. It discusses the board's decision and compliance with legal and procedural requirements. The content focuses on a capital market financing decision and the termination of a share issuance plan, not the issuance itself or detailed financial data. The document length is short (578 characters), and it is an announcement related to capital/financing activities rather than a full report or detailed financial statement. Therefore, it fits best under Capital/Financing Update (CAP).
2022-06-28 Chinese
关于终止向特定对象发行股票事项并撤回申请材料的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Beijing Northland Biotechnology Co., Ltd. regarding the termination of a planned private placement of shares and the withdrawal of related application materials. It details board and supervisory committee meetings, independent director opinions, and the impact of the termination on the company. The content focuses on a capital raising activity that was planned but is now being stopped. There are no financial statements or detailed financial data presented, and the document is relatively short (1512 characters). This is a clear update on a capital/financing activity rather than a full financial report or earnings release. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2022-06-28 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.